文献速递骨肿瘤

下肢骨肉瘤假体置换重建术后手术部位感染与1年无进展生存无关:PARITY研究数据的二次分析

Surgical Site Infection Is Not Associated with 1-Year Progression-Free Survival After Endoprosthetic Reconstruction for Lower-Extremity Osteosarcoma: A Secondary Analysis of PARITY Study Data.
PubMed 文献 · J Bone Joint Surg Am · 2023-07-19

该研究为PARITY随机对照试验的二次分析,纳入274例下肢骨肉瘤行假体置换重建的患者,其中53例(19.3%)发生手术部位感染(SSI)。总体1年无进展生存(PFS)在感染与未感染患者间无差异;基线转移患者中感染与1年疾病进展风险升高相关(HR=4.26,95%CI 1.11-16.3),而基线局限性疾病患者中未见关联(HR=1.21,95%CI 0.64-2.28)。

要点

  • 274例骨肉瘤患者中53例(19.3%)发生SSI,总体1年PFS在感染与未感染患者间无差异。
  • 基线局限性疾病患者中,SSI与1年疾病进展无显著关联(HR=1.21,95%CI 0.64-2.28)。
  • 基线转移患者中,感染与1年疾病进展风险升高相关(HR=4.26,95%CI 1.11-16.3)。

核心结论

  • 在此项前瞻性数据的二次分析中,术后感染与手术后1年PFS之间未检测到正相关。
  • 该分析提示感染可能是基线转移患者早期疾病进展的危险因素,未来研究可能更好地阐明疾病负荷与宿主免疫应答之间的关联,以推进骨肉瘤免疫治疗策略。

研究设计与样本

  • PARITY试验为国际、多中心、前瞻性随机对照试验,共604例患者接受下肢骨肿瘤切除与假体置换重建。
  • 本二次分析纳入274例骨肉瘤患者,采用Cox比例风险模型分析临床与肿瘤特征、SSI与PFS的关联,Kaplan-Meier分析用于确定SSI对PFS的影响。
  • 按就诊时疾病分期和感染严重程度进行亚组分析。

主要发现

  • 274例骨肉瘤患者中,32例(11.7%)基线时存在转移,53例(19.3%)发生SSI。
  • 感染与未感染患者之间1年PFS无差异。
  • 基线局限性疾病且发生SSI的患者1年疾病进展风险未降低(HR=1.21,95%CI 0.64-2.28)。
  • 基线转移患者中,感染与1年疾病进展增加相关(HR=4.26,95%CI 1.11-16.3)。

关键数值与推荐

  • 主要结局为骨肉瘤患者术后1年无进展生存(PFS)。
  • 证据等级为预后Level II。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although there is evidence suggesting that postoperative infection confers a survival benefit in osteosarcoma treated with resection and endoprosthetic reconstruction, there have been no prospective studies to date to support these findings. This secondary analysis of Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) study data examines the relationship between surgical site infection (SSI) and disease progression within 12 months after limb salvage surgery. METHODS: The PARITY trial was an international, multicenter, prospective randomized controlled trial of 604 patients who underwent resection of a lower-extremity bone tumor and endoprosthetic reconstruction. Our primary outcome was progression-free survival (PFS) at 1 year following surgery among the patients with osteosarcoma. Subgroup analyses by disease stage at presentation and infection severity were also performed. Cox proportional hazard models were employed to examine the association between clinical and tumor characteristics, SSI, and PFS. Kaplan-Meier analysis was used to determine the effect of SSI on PFS. RESULTS: The 274 PARITY patients with osteosarcoma were included in this secondary analysis. Thirty-two (11.7%) of the patients presented with metastasis at baseline; 53 (19.3%) of the patients developed an SSI. There was no difference in 1-year PFS between patients with and without SSI. There was no decreased risk of disease progression at 1 year in patients with localized disease at baseline who developed an SSI (hazard ratio [HR] = 1.21; 95% confidence interval [CI] = 0.64 to 2.28). Infection was associated with increased disease progression at 1 year in patients with baseline metastases (HR = 4.26; 95% CI = 1.11 to 16.3). CONCLUSIONS: No positive association was detected between postoperative infection and PFS at 1 year following surgery in this secondary analysis of prospective data. However, this analysis suggests infection could be a risk factor for early disease progression in patients with baseline metastases, and future investigations may better elucidate the association between disease burden and the host immune response to advance immunotherapeutic strategies for osteosarcoma. LEVEL OF EVIDENCE: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Jackson KJ, Sullivan CD, Zimel MN, et al. Surgical Site Infection Is Not Associated with 1-Year Progression-Free Survival After Endoprosthetic Reconstruction for Lower-Extremity Osteosarcoma: A Secondary Analysis of PARITY Study Data. J Bone Joint Surg Am. 2023. PMID: 37466580. doi:10.2106/JBJS.22.01077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。